Standard Biomarkers for Pleural Mesothelioma “Not Useful” for Immunotherapy
| | | |

Standard Biomarkers for Pleural Mesothelioma “Not Useful” for Immunotherapy

Two of the most important biomarkers for pleural mesothelioma are not much help when it comes to tracking response to immunotherapy. Top mesothelioma researchers at the University of Pennsylvania drew that conclusion based on data from a cohort of 58 patients.  They focused on two primary biomarkers for pleural mesothelioma: SMRP and fibulin-3. Doctors use both of these markers to diagnose and plan treatment for mesothelioma.  The study confirms the correlation between these markers and mesothelioma tumor volume. But the Penn Medicine researchers say these biomarkers of pleural mesothelioma were “not useful” for measuring immunotherapy response. Understanding Biomarkers for Pleural Mesothelioma A biomarker is a substance produced by the body that indicates a biological process or condition. Most mesothelioma biomarkers…